Texas Permanent School Fund lifted its holdings in shares of Amedisys Inc (NASDAQ:AMED) by 10.7% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,900 shares of the health services provider’s stock after buying an additional 2,109 shares during the period. Texas Permanent School Fund owned about 0.07% of Amedisys worth $2,869,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Rehmann Capital Advisory Group acquired a new position in shares of Amedisys during the 2nd quarter worth $31,000. CWM LLC raised its holdings in shares of Amedisys by 482.2% during the 2nd quarter. CWM LLC now owns 262 shares of the health services provider’s stock worth $32,000 after buying an additional 217 shares in the last quarter. Tompkins Financial Corp acquired a new position in shares of Amedisys during the 2nd quarter worth $37,000. Point72 Asset Management L.P. acquired a new position in shares of Amedisys during the 2nd quarter worth $49,000. Finally, Maverick Capital Ltd. acquired a new position in shares of Amedisys during the 2nd quarter worth $54,000. 88.11% of the stock is owned by institutional investors.
A number of equities analysts have recently commented on the company. Raymond James boosted their price target on Amedisys from $140.00 to $144.00 and gave the stock an “outperform” rating in a report on Monday, July 15th. BidaskClub raised Amedisys from a “buy” rating to a “strong-buy” rating in a report on Friday, July 26th. Deutsche Bank started coverage on Amedisys in a report on Monday, September 16th. They set a “buy” rating and a $155.00 price target for the company. ValuEngine cut Amedisys from a “buy” rating to a “hold” rating in a report on Thursday, September 26th. Finally, Oppenheimer upped their target price on Amedisys from $140.00 to $150.00 in a report on Thursday, August 1st. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $145.36.
Shares of AMED opened at $148.33 on Friday. Amedisys Inc has a 12-month low of $103.76 and a 12-month high of $154.14. The business has a 50-day simple moving average of $133.29 and a two-hundred day simple moving average of $126.21. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.48. The stock has a market cap of $4.73 billion, a PE ratio of 40.86, a PEG ratio of 2.03 and a beta of 1.38.
Amedisys (NASDAQ:AMED) last issued its earnings results on Tuesday, October 29th. The health services provider reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.25. Amedisys had a return on equity of 26.53% and a net margin of 6.70%. The business had revenue of $494.63 million during the quarter, compared to analysts’ expectations of $494.14 million. During the same quarter in the prior year, the firm earned $0.95 EPS. The business’s revenue for the quarter was up 18.5% compared to the same quarter last year. On average, equities research analysts expect that Amedisys Inc will post 4.39 EPS for the current year.
In other news, COO Christopher Gerard sold 350 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $128.79, for a total value of $45,076.50. Following the completion of the sale, the chief operating officer now owns 25,239 shares of the company’s stock, valued at $3,250,530.81. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jake L. Netterville sold 1,000 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $135.64, for a total value of $135,640.00. Following the completion of the sale, the director now directly owns 72,700 shares of the company’s stock, valued at approximately $9,861,028. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,050 shares of company stock valued at $278,696. Insiders own 2.90% of the company’s stock.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Story: What is the CBOE Russell 2000® Volatility Index?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.